Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Faluyi, O"'
Autor:
Neoptolemos, J.P., Palmer, D.H., Ghaneh, P., Psarelli, E.E., Valle, J.W., Halloran, C.M., Faluyi, O., O'Reilly, D.A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J.R., Middleton, G.W., Cummins, S., Ross, P.J., Wasan, H., McDonald, A., Crosby, T., Ma, Y.T., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Hackert, T., Jackson, R., Büchler, M.W., European Study Group for Pancreatic Cancer
BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials have sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::1ec5e6e466b47b4a92503f735b35583d
https://eprints.whiterose.ac.uk/114332/1/1-s2.0-S0140673616324096-main.pdf
https://eprints.whiterose.ac.uk/114332/1/1-s2.0-S0140673616324096-main.pdf
Autor:
Neoptolemos JP; University of Liverpool, Liverpool, UK; The Royal Liverpool University Hospital, Liverpool, UK. Electronic address: j.p.neoptolemos@liverpool.ac.uk., Palmer DH; University of Liverpool, Liverpool, UK; The Clatterbridge Cancer Centre, Wirral, UK., Ghaneh P; The Royal Liverpool University Hospital, Liverpool, UK., Psarelli EE; University of Liverpool, Liverpool, UK., Valle JW; University of Manchester/The Christie NHS Foundation Trust, Manchester, UK., Halloran CM; University of Liverpool, Liverpool, UK; The Royal Liverpool University Hospital, Liverpool, UK., Faluyi O; The Clatterbridge Cancer Centre, Wirral, UK., O'Reilly DA; Manchester Royal Infirmary, Manchester, UK., Cunningham D; Royal Marsden Hospital, London, UK., Wadsley J; Weston Park Hospital, Sheffield, UK., Darby S; Weston Park Hospital, Sheffield, UK., Meyer T; Royal Free Hospital, London, UK., Gillmore R; Royal Free Hospital, London, UK., Anthoney A; St James's University Hospital, Leeds, UK., Lind P; Karolinska Institute, Stockholm, Sweden; Clinical Research Sörmland, Eskilstuna, Sweden., Glimelius B; University of Uppsala, Uppsala, Sweden., Falk S; Bristol Haematology and Oncology Centre, Bristol, UK., Izbicki JR; University of Hamburg Medical institutions UKE, Hamburg, Germany., Middleton GW; Royal Surrey County Hospital, Guildford, UK., Cummins S; Royal Surrey County Hospital, Guildford, UK., Ross PJ; Guy's Hospital, London, UK., Wasan H; Hammersmith Hospital, London, UK., McDonald A; The Beatson West of Scotland Cancer Centre, Glasgow, UK., Crosby T; Velindre Hospital, Cardiff, UK., Ma YT; Queen Elizabeth Hospital, Birmingham, UK., Patel K; Churchill Hospital, Oxford, UK., Sherriff D; Derriford Hospital, Plymouth, UK., Soomal R; Ipswich Hospital, Ipswich, UK., Borg D; Skåne University Hospital, Lund, Sweden., Sothi S; University Hospital Coventry, Coventry, UK., Hammel P; Hôpital Beaujon, Clichy, France., Hackert T; University of Heidelberg, Germany., Jackson R; University of Liverpool, Liverpool, UK., Büchler MW; University of Heidelberg, Germany.
Publikováno v:
Lancet (London, England) [Lancet] 2017 Mar 11; Vol. 389 (10073), pp. 1011-1024. Date of Electronic Publication: 2017 Jan 25.